OncoMatch/Clinical Trials/NCT06925464
CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
Is NCT06925464 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CD7 CAR-T cells infusion for t-cell non-hodgkin lymphoma.
Treatment: CD7 CAR-T cells infusion — This is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD7 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD7 CAR T cell bridging to HSCT in the treatment of r/r T-NHL. The primary endpoint is the type and incidence of dose limiting toxicity (DLT) within 21 days after CD7 CAR-T cell infusion. A total of 36 subjects is estimated to be enrolled.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD7 overexpression (positive)
Relapsed or refractory CD7-positive T-cell lymphomas
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy
treated with with standard chemotherapy, with poor prognosis from currently available treatments at and no available treatment options (e.g., HSCT or chemotherapy)
Lab requirements
Kidney function
serum creatinine and/or urea nitrogen < 1.5 times the normal value
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify